Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Kursexplosion von 383 % seit November und massiver Solana-Outperformer!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
164 Leser
Artikel bewerten:
(1)

Cariny Camacho Appointed as Chief Human Resources Officer for Chromalloy

Finanznachrichten News

PALM BEACH GARDENS, FLORIDA / ACCESS Newswire / January 22, 2025 / Chromalloy is pleased to announce the appointment of Cariny Camacho to the role of Chief Human Resources Officer (CHRO).

Cariny Camacho, Chromalloy CHRO

Cariny Camacho, Chromalloy CHRO
Cariny Camacho Appointed as Chief Human Resources Office for Chromalloy

Cariny is a distinguished human resource professional with extensive experience in driving cultural change, implementing strategic human resources operating systems, managing organizational development, and partnering with operating leadership for talent management and development. She has earned a reputation for fostering high-performing teams and building inclusive, dynamic workplace cultures.

Chris Celtruda, CEO of Chromalloy, remarked, "Cariny's dedication to excellence will be instrumental in driving our human resources initiatives forward. We are looking to drive a competitive, velocity-driven culture that accepts change and is ready to confront business challenges. I expect her approach to talent acquisition and development will help us build a culture that positions us for future growth."

In her most recent role as Senior Director, HRBP Southeast Region at Quest Diagnostics, she worked closely with senior-level business leaders to align human resource strategies with organizational goals. Her leadership significantly contributed to workforce productivity, employee engagement, and operational excellence. Key achievements included implementing comprehensive employee engagement surveys to enhance retention and productivity, driving organizational re-design and talent management strategies to meet long-term business objectives, and coaching senior leaders through complex change initiatives while ensuring alignment with ethical and legal standards.

Prior to Quest Diagnostics, she held pivotal roles at Kellstrom Defense Aerospace, Inc. and Ametek, where she led human resource operations, workforce planning, and leadership development initiatives. She has experience building university and community relations programs, being the architect for a high potential leader development program and has been involved extensively in acquisition workforce integration.

Cariny, an alumna of York College, CUNY, holds a Bachelor of Business Administration in Human Resources Management.

"I am passionate about creating workplaces where employees feel valued, empowered, and motivated to contribute to their fullest potential," said Cariny. "I believe that people and the development of our global team will enable the growth expectations of the business in the coming years."

About Chromalloy

Chromalloy is a leading provider of engineering, manufacturing, and service for the aerospace, aero-derivative, and energy/industrial gas turbine aftermarket. For over 70 years, Chromalloy has been a trusted partner of airlines, aero-engine asset owners, and engine repair facilities. Chromalloy is a leader in FAA-certified, third-party PMA and DER solutions to enable customer value during engine restoration and maintenance. The combination of alternative PMA new parts, DER part repairs, and inventory of used serviceable material (USM) enables each engine overhaul to achieve expected performance and achieve best value. Operating from over 20 locations worldwide, Chromalloy remains committed to having the right global team, available inventory, and a bias for addressing service needs for legacy and midlife engines. Our investments in design engineering, testing, and component manufacturing ensure that all regulatory and performance criteria are met or exceeded.

For additional information, visit www.chromalloy.com.

Contact Information

Julie Sims
Vice President, Marketing and Communications
jsims@chromalloy.com
561.935.3571

.

SOURCE: Chromalloy



View the original press release on ACCESS Newswire

© 2025 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.